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A B S T R A C T
Objectives: Women with a previous hypertensive disorder of pregnancy (HDP: gestational hypertension and
preeclampsia) have increased long-term cardiovascular disease risk. Recent meta-analyses show adverse levels of
non-invasive functional and structural cardiovascular risk markers such as pulse wave velocity (PWV), heart-rate
adjusted augmentation index (AIx75), carotid intima-media thickness (CIMT), and reactive hyperemia index
(RHI) after HDPs, and suggest using these for cardiovascular risk stratification. However, it is not known if a
previous HDP predict levels of these markers beyond classical cardiovascular risk factors.
Study design and main outcome measures. We assessed PWV, AIx75, CIMT, RHI, classical cardiovascular risk
factors, and pregnancy characteristics in 221 women 1 year postpartum (controls: 95, previous HDP: 126). Uni-
and multi- variate regression analysis were conducted to assess associations between previous HDP and PWV,
AIx75, CIMT or RHI. We adjusted for classical cardiovascular risk factors and pregnancy characteristics. A p-
level < 0.05 was considered statistically significant.
Results: PWV was associated with previous HDP on univariate analysis. This effect was confounded by blood
pressure and not significant after adjustment. We found no significant associations between AIx75, RHI, CIMT,
and a previous HDP, neither before nor after adjustments.
Conclusions: Associations between a previous HDP and PWV, AIx75, CIMT, or RHI 1 year postpartum can largely
be explained by adverse levels of classical cardiovascular risk markers in women with a previous HDP. Women
with previous HDP should receive primary prevention of cardiovascular disease, but PWV, AIx75, CIMT or RHI
are unlikely to aid in cardiovascular risk stratification 1 year postpartum.
1. Introduction
A previous hypertensive disorder of pregnancy (HDP) like pre-
eclampsia or gestational hypertension (GH) confers an increased risk of
later maternal cardiovascular disease [1]. An HDP often precedes the
debut of clinical cardiovascular disease by decades, and many types of
cardiovascular disease can be prevented or postponed by timely inter-
vention, justifying cardiovascular follow-up of women with a previous
HDP [1,2].
Methods to identify the women with a previous HDP who will
benefit the most by preventive interventions are not readily available. It
is recommended to assess long-term cardiovascular disease risk using
risk calculators [2,3], but we have previously shown that these fail to
reflect the epidemiologically increased cardiovascular risk when ap-
plied 1 year postpartum [4].
Several studies have identified adverse levels of vascular markers
such as pulse wave velocity (PWV), augmentation index, and carotid
intima-media thickness (CIMT), and reactive hyperemia index (RHI) in
women with a previous HDP [5–8]. Some have suggested that these
could identify women at the highest risk and guide preventive measures
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[5,6,9]. However, the ability of these markers to predict cardiovascular
disease in women with previous HDPs has not been documented. It is
also unclear if these markers predict cardiovascular disease beyond
classical, and routinely available cardiovascular risk factors such as
dyslipidemia, smoking, age, body mass index (BMI), and blood pressure
[2,3,10].
The aim of this study was to evaluate levels of RHI, PWV, heart-rate
adjusted augmentation index (AIx75), and CIMT in women with a re-
cent pregnancy complicated by HDP, to compare levels of women with
normotensive index pregnancies, and to investigate if potential asso-
ciations were independent of classical cardiovascular risk factors.
2. Methods
All procedures were in accordance with institutional guidelines and
with the Declaration of Helsinki. The Regional Committee for Medical
and Health Research Ethics of South East Norway approved the study.
All women provided written informed consent.
Women above 18 years who had delivered a singleton baby without
congenital malformations at Oslo University Hospital, Ullevål, Norway,
were invited to participate in the Health after pregnancy complications
study 1 year postpartum. Women with diabetes, cardiovascular disease
(except for HDP), renal or rheumatic disease, were excluded as these
diseases may impact on CVD risk. We also excluded women who were
still breastfeeding or pregnant at postpartum exam time.
Gestational age at the index delivery was based on routine ultra-
sound examination at gestational week 18–20, except for 18 pregnan-
cies (2 by the first day of last menstruation prior to pregnancy and 16
by in vitro fertilization dating).
Gestational hypertension (GH) and preeclampsia in the index
pregnancy were defined by the International Society for the Study of
Hypertensive Disorders in Pregnancy guidelines [11]. GH is defined as
new-onset hypertension after gestational week 20 while preeclampsia is
defined by the addition of either new-onset proteinuria or other pre-
eclampsia-associated organ dysfunction signs (including elevated liver
transaminases and fetal growth restriction) [11]. Since previous studies
comparing the same vascular cardiovascular markers between women
with a previous HDP and parous controls have used the old pre-
eclampsia-definition requiring mandatory new-onset proteinuria in
addition to gestational hypertension, we also present a supplement
applying this definition. Preterm and term preeclampsia were defined
by delivery before or from 37th gestational weeks, respectively. The in-
patient hospital blood pressure used to diagnose HDP was based on
repeated measurement with a validated device (Dinamap Pro, 100VE,
GE Medical Systems Information Technology, Inc. Milwaukee, WI, USA)
[12].
Delivery of a small for gestational age (SGA) baby was defined as a
baby below the 3rd birth weight percentile, adjusted for gestational age
at delivery and fetal sex [13]. Controls were normotensive prior to and
throughout any pregnancy and delivered a non-SGA baby from 37 ge-
stational weeks onwards. None of the included women showed signs of
hyperglycemia during pregnancy.
Fasting (≥6 h) morning serum samples were collected for all par-
ticipants 1 year postpartum. Total cholesterol, low density lipoprotein
cholesterol (LDL), high density lipoprotein cholesterol (HDL), and
glucose were analyzed according to clinical routine by the Department
of Clinical Biochemistry, Oslo University Hospital. Cholesterol, LDL and
HDL were measured by an enzymatic colorimetric method (cobas 8000
c702, Roche Diagnostics).
At the 1 year postpartum exam, blood pressure was measured in the
right upper arm with an identical blood pressure device as prior to
delivery following guidelines from the European Society of
Hypertension and European Society of Cardiology [14]. Height and
weight were measured, and questionnaires regarding pregnancies be-
fore index pregnancy, cardiovascular health, cardiovascular risk fac-
tors, general health, and socioeconomic factors completed. Body mass
index (BMI) was defined as weight divided on squared height.
Examinations were performed in fasting (≥6 h) women in supine
position in a temperature-regulated, quiet room with dimmed lights
and with at least 10 min bedrest before PWV, AIx75, and RHI-assess-
ments.
Four trained examinators assessed endothelial function using
EndoPAT™-2000 (Itamar Medical Ltd., Caesarea, Israel). The RHI, a
standardized post-occlusion to pre-occlusion-ratio, was calculated by
the software. Lower RHI is associated with poorer endothelial function
[15]. We assessed carotid-femoral PWV using Sphygmocor® CvMS,
version 9 (AtCor Medical, Sydney, Australia) according to guidelines
[16]. AIx75 was assessed with the same device. Carotid Intima-Media
Thickness (CIMT) was measured using the multiarray echotracking
system (Art.Lab®, Esaote, Maastricht, the Netherlands) equipped with a
10–5 MHz linear array. Measurements were performed according to
guidelines from the European Stroke Conferences [17]. Details of the
methods are presented in the supplemental file.
One examiner (KM) conducted all PWV, AIx75, and CIMT ex-
aminations. We have previously assessed reproducibility of PWV, AIx75
and CIMT by the intraclass correlation coefficient based on a mean-
rating, absolute-agreement, 2-way mixed-effects model. All intraclass
correlation coefficients were “excellent”: PWV (0.930, 95%CI:
0.822–0.972, p < 0.001), AIx75 (0.985, 95%CI: 0.963–0.994,
p < 0.001), and CIMT (ICC: 0.977, 95%CI: 0.937–0.991, p < 0.001).
Statistical analyses were performed with the Statistical Package for
the Social Sciences (PASW Statistics 25). As most variables were not
normally distributed, medians and ranges are presented. Differences
between groups were tested with Mann-Whitney U test for continuous
and Chi-square or Pearson’s mid-corrected p-test for categorical vari-
ables. A p-value of < 0.050 was considered statistically significant for
an association between the dependent and independent variable.
Univariate linear regression analysis was used to analyze associa-
tions between HDPs and the levels of PWV, AIx75, CIMT, and RHI.
Multivariate linear regression analysis was used to adjust for possible
confounders identified prior to the analyses based on previous litera-
ture. Continuous possible confounders were mean-centered. Age and
BMI were introduced by forced entry in model 2. In model 3, we ad-
ditionally introduced cardiovascular risk marker variables commonly
used for cardiovascular disease risk stratification [18,19] if significant
(p < 0.10) on univariate analysis. These were included in the final
multivariate model if significant (p < 0.05). For model 4, we ad-
ditionally introduced pregnancy characteristics variables associated to
cardiovascular diseaserisk [20,21] in the same way as in model 3.
Hence, we present 4 models: unadjusted, adjusted for age and BMI, also
adjusted for classical cardiovascular risk markers, and finally also ad-
justed for pregnancy characteristics. Fig. 1 presents the variables used
in the regression analyses.
Power appeared to be sufficient based on previous studies in-
vestigating the same markers in similar populations [7,9,22,23].
3. Results
Table 1 summarizes the clinical characteristics of the totally 221
women examined 1 year postpartum (2014–2018). The HDP group
(n = 126) included 88 women with preeclampsia (54 with term and 34
with preterm preeclampsia) or GH (n = 38) in their index pregnancy.
Median follow-up time was 13.8 months, and in median 19 days shorter
in term preeclampsia women compared to controls. In all groups most
women were of white ethnicity and educated beyond high school level.
Both term (n = 3) and preterm (n = 5) preeclampsia pregnancies
were complicated by HELLP (hemolysis, elevated liver enzymes, and
low platelets). The rates of SGA babies and primiparity were as ex-
pected higher for the previous preeclampsia groups.
At 1 year postpartum all groups with previous HDPs exhibited a
worse cardiovascular disease risk profile with significantly higher dia-
stolic and systolic blood pressures compared to controls (Table 1).
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Prehypertension and hypertension were significantly more common in
all groups with a previous HDP, though not significantly for hy-
pertension in term preeclampsia women. In women with previous GH,
nearly half were either hypertensive or prehypertensive at follow-up.
Two women (one with term preeclampsia and one with GH) were
identified with untreated hypertension, necessitating follow-up.
BMI was higher within all previous HDP groups, although only
significant for the total HDP group when compared to controls.
Overweight and cardiovascular disease in a 1st degree relative were
more common in all groups with previous HDP, but not significantly so
in the group with previous GH.
Due to technical failure of obtaining a technically satisfying result,
or time constraint, PWV was analyzed in 86.0%, AIx75 in 87.3%, RHI in
95.4%, and CIMT in 90.5% of the women. All included women had at
least one valid type of examination (Details are presented in Table 2)
Table 2 also presents the unadjusted analysis when applying the old
preeclampsia definition requiring proteinuria.
Mean values of PWV, AIx75, and CIMT for controls were consistent
with published reference ranges for premenopausal women [24–26],
while no reference values for RHI exist. Unadjusted results for the
vascular markers for the different pregnancy groups are presented in
Table 2.
PWV was significantly higher in the total group with HDP and in the
subgroups with preterm preeclampsia and GH as compared to controls
(Table 2). Although AIx75 and CIMT levels were higher in all groups
with a previous HDP as compared to parous controls, none of these
differences were significant (Table 2). For RHI, there were no sig-
nificant differences in any group of pregnancy complication.
As shown in Table 3 and Fig. 2, we found no significant association
between adverse levels of vascular markers for the total HDP group or
for any of the HDP subgroups after adjustments in the multivariate
regression analysis (Model 2–4).
For PWV, adjusting for diastolic blood pressure heavily mediated
the association between PWV and a previous HDP. This was also the
case for the HDP subgroups (Model 3). After this adjustment, neither
the total HDP group nor any subgroup were significant independent
predictors of PWV, and only BMI and age remained significant pre-
dictors of PWV at 1-year postpartum. No pregnancy factor was a sig-
nificant predictor of PWV within the total HDP group or in any HDP
subgroup (Model 4).
For AIx75, although the effect of an HDP on AIx75 levels increased
in all groups after adjustment for age and BMI, still no association was
significant (Model 2). Further adjustment for cardiovascular risk factors
and pregnancy characteristics showed mediation from the
Fig. 1. Variables included in the regression analyses. HDL-cholesterol: High
Density Lipoprotein Cholesterol. LDL-cholesterol: Low Density Lipoprotein
Cholesterol.
Table 1
Clinical data one-year postpartum.
Controls (n = 95) Hypertensive Disorder of
Pregnancy (n = 126)
Term Preeclampsia (n = 54) Preterm Preeclampsia
(n = 34)
Gestational Hypertension
(n = 38)
Age (years) 34.9 23.5–43.7 34.2 21.7–45.1 34.3 21.7–43.3 34.9 24.5–43.2 34.0 23.0–45.1
BMI (kg/m2) 22.7 17.1–36.0 23.9* 18.3–37.6 24.1 19.9–37.6 24.6 18.3–32.5 23.7 18.9–33.7
Overweight (BMI > 25 kg/m2) 28.4% 27 46.0%* 58 44.4%* 24 50.0%* 17 44.7% 17
Systolic BP (mmHg) 106 90–122 114† 94–145 112† 94–140 114† 94–133 118† 99–145
Diastolic BP (mmHg) 62 53–82 71† 51–96 68† 56–84 71† 51–86 73† 53–96
Prehypertensive (BP 120–139/
80–89 mmHg)
2.1% 2 27.0%† 34 20.4%† 11 20.6% 7* 42.1%† 16
New/treated hypertension 0.0% 0 4.8%* 6 3.8% 2 5.9%* 2 5.2%* 2
Antihypertensive use 1.1% 1 3.2% 4 1.9% 1 5.9% 2 2.6% 1
Smoking 9.6% 9 8.9% 11 3.8% 2 8.8% 3 16.2% 6
LDL-cholesterol (mg/dL) 103.5 59.1–202.7 105.4 44.4–184.9 104.8 59.5–185.0 110.4 44.4–184.6 102.1 48.3–156.5
HDL-cholesterol (mg/dL) 59.3 38.6–113.1 58.3 27.4–93.4 57.1 38.2–93.4 58.3 27.4–89.6 59.7 30.9–82.2
Cholesterol (mg/dL) 171.8 104.3–281.9 173.7 108.1–262.5 169.9 123.6–247.1 181.5 115.8–262.6 173.8 108.1–239.4
Premature CVD in 1st degree
relative
16.8% 16 31.7%* 40 33.3%* 18 38.2%* 13 23.7% 9
Education > high school 91.7% 77 87.1% 101 91.7% 44 86.7% 26 81.6% 31
White/not stated ethnicity 94.7% 90 95.7% 112 96.3% 52 94.1% 32 97.4% 37
SGA in index pregnancy (< 3rd
percentile)
0.0% 0 26.2%† 33 24.1%† 13 58.8%† 20 0.0% 0
Female offspring in index
pregnancy
56.8% 54 46.8% 59 50.0% 27 41.2% 14 47.4% 18
Gestational age at delivery in
index pregnancy (days)
275 261–296 268† 177–293 271* 259–291 233† 177–257 278 261–293
Primiparous 45.3% 43 71.4%† 90 79.6%† 43 67.6%* 23 63.2% 24
Follow-up time from index
pregnancy (days)
420 342–543 407† 296–492 401* 296–492 419 346–484 417 327–487
BP: Blood Pressure. BMI: Body Mass Index. LDL: Low Density Lipoprotein. HDL: High Density Lipoprotein. CVD: Cardiovascular Disease. SGA: Small for Gestational
age. Mann Whitney U test for continuous variables and Chi-square or Fisher's mid-p corrected test for categorical variables comparing pregnancy complication (e.g.
GH) to controls: *:p-value < 0.050. †:p-value < 0.001.
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cardiovascular risk factors; in particular diastolic blood pressure.
Systolic blood pressure was in addition a significant predictor in the
total HDP group. No pregnancy factor was a significant predictor of
AIx75 within the total HDP group or in any HDP subgroup (Model 4).
For CIMT, antihypertensive use was a significant positive predictor
of CIMT in the total HDP group, and in the preterm preeclampsia group,
while LDL levels were only significant in the total HDP group. No
pregnancy factor was a significant predictor of CIMT within any group.
For RHI, smoking was a significant predictor of low RHI in the term
preeclampsia and GH groups, but only mediating the effect of term
preeclampsia on RHI. Smoking was also mediating the effect of any
previous HDP on RHI. In this comparison, diastolic blood pressure was
also a significant predictor. When adjusting for pregnancy character-
istics, delivery of an SGA baby mediated the effect of term preeclampsia
on RHI. The same was the case for delivery of an SGA baby in the total
HDP group. Here, primiparity was also a significant predictor.
As rates of delivery of an SGA baby and primiparity differed sig-
nificantly between HDPs and controls, we also tested for interactions
between HDPs and delivery of an SGA baby or primiparity, but no in-
teraction was significant for any of the vascular markers.
Significant covariates in the multivariate regression analyses are
presented in Supplemental Table 1. The regression analyses for AIx75
and CIMT contained outliers impacting the effect estimates. For AIx75
this was a control (AIx75: 11%), and for CIMT a woman with previous
preterm preeclampsia (CIMT: 888 μm). Regression analyses excluding
these two women (Supplemental Table 2) show that the effect estimates
are heavily impacted by these observations, though the non-sig-
nificance of the associations to the outcomes was not altered.
Using the old preeclampsia definition requiring proteinuria pro-
duced similar results for relations between the vascular markers and
previous HDPs (Table 2).
4. Discussion
This study shows that 1 year postpartum a previous HDP is asso-
ciated with adverse pulse wave velocity (PWV) levels, but neither with
levels of heart-rate adjusted augmentation index (AIx75), carotid in-
tima-media thickness (CIMT), nor with reactive hyperemia index (RHI)
levels. After adjustment for classical cardiovascular disease risk factors,
no association between a previous HDP and PWV, AIx75, CIMT, or RHI
was significant. In detail, PWV was higher 1 year after a pregnancy
complicated by preterm preeclampsia or GH, but not term pre-
eclampsia. No difference was significant after adjusting for classical
cardiovascular risk factors.
Our study was designed for prospectively assessing cardiovascular
outcomes after pregnancy complications. It is strengthened by the ex-
tensive cardiovascular and pregnancy data collected in a standardized
way. This enabled us to adjust for common cardiovascular risk markers
Table 2
Reactive Hyperemia Index, Pulse Wave Velocity, Augmentation Index adjusted for a Heart Rate of 75 Beats per Minute, and Carotid Intima-Media Thickness in
Women with index Pregnancy Hypertensive Disorder of Pregnancy and Parous Controls 1 Year postpartum. Values are given as Median (Range) and Number.
PWV (m/s) AIx75 (%) CIMT (μm) RHI
Controls 5.78 (4.30–8.60) 80 11 (−15–28) 80 450 (353–676) 91 1.90 (1.05–3.08) 90
Hypertensive Disorder of Pregnancy 6.10† (4.50–8.35) 110 12 (−12–31) 113 464 (353–888) 119 1.89 (1.00–2.91) 121
Term Preeclampsia 6.10 (4.50–8.35) 47 10 (−5–31) 47 460 (367–676) 51 2.06 (1.03–2.91) 52
Term Preeeclampsia* 6.08 (4.50–8.35) 42 10 (−5–31) 43 461 (367–676) 46 2.07 (1.03–2.91) 47
Preterm Preeclampsia 6.35† (4.70–8.30) 30 13 (-6–27) 31 461 (376–888) 32 1.84 (1.00–2.73) 31
Preterm Preeclampsia* 6.40†(4.90–8.30) 27 13 (-6–27) 27 461 (376–888) 28 1.90 (1.00–2.73) 27
Gestational Hypertension 6.10 †(4.55–8.20) 33 13 (−12–27) 35 480 (353–634) 36 1.81 (1.05–2.55) 38
Gestational Hypertension* 6.10† (4.55–8.20) 41 12 (−12–27) 43 465 (353–634) 45 1.75 (1.05–2.55) 47
RHI: Reactive Hyperemia Index. PWV: Pulse Wave Velocity. AIx75: Augmentation Index adjusted for heart rate of 75 beats per minute. CIMT: Carotid Intima-Media
Thickness. *: using definition of preeclampsia requiring proteinuria. †: p < 0.050 comparing controls with hypertensive disorder of pregnancy (e.g. late pre-
eclampsia) using Mann-Whitney U test
Table 3
Regression analysis comparing levels of PWV, AIx75, CIMT, and RHI, in women with previous HDP to parous controls.
Controls vs. Hypertensive Disorders of
Pregnancy
Controls vs. Term Preeclampsia Controls vs. Preterm Preeclampsia Controls vs. Gestational Hypertension
Model B 95%CI B 95%CI B 95%CI B 95%CI
PWV (m/s) 1 0.35† (0.12–0.59) 0.25 (−0.03–0.54) 0.50† (0.16–0.84) 0.36* (0.03–0.68)
n = 190 2 0.33† (0.11–0.55) 0.26 (−0.01–0.53) 0.45† (0.13–0.77) 0.35* (0.03–0.67)
3 0.02 (−0.19–0.24) 0.04 (−0.23–0.31) 0.13 (−0.10–0.36) −0.01 (−0.04–0.02)
4 0.02 (−0.19–0.24) −0.01 (−0.28–0.27) 0.13 (−0.10–0.36) −0.01 (−0.04–0.02)
AIx75 (%) 1 1.8 (−0.9–4.5) 1.2 (−2.2–4.7) 3.0 (−1.1–7.1) 1.5 (−2.5–5.6)
n = 193 2 2.2 (−0.3–4.7) 2.3 (−0.9–5.4) 3.3 (−0.6–7.2) 2.2 (−1.5–5.9)
3 0.8 (−1.9–3.4) 0.4 (−2.9–3.6) 0.3 (−4.1–4.6) −0.5 (−4.8–3.8)
4 0.8 (−1.9–3.4) 0.4 (−2.9–3.6) 0.3 (−4.1–4.6) −0.5 (−4.8–3.8)
CIMT (μm) 1 11 (−9–30) 7 (−17–30) 14 (−15–43) 13 (−11–38)
n = 210 2 9 (−10–28) 6 (−17–28) 12 (−17–40) 12 (−12–35)
3 10 (−9–28) 6 (−17–28) 5 (–23–33) 12 (−12–35)
4 10 (−9–28) 6 (−17–28) 5 (–23–33) 12 (−12–35)
RHI 1 −0.04 (−0.16–0.08) 0.05 (−0.11–0.21) −0.10 (−0.28–0.08) −0.12 (−0.29–0.05)
n = 211 2 −0.06 (−0.18–0.06) 0.04 (−0.12–0.20) −0.11 (-0.30–0.07) −0.13 (−0.30–0.04)
3 −0.01 (−0.14–0.12) 0.02 (−0.14–0.18) −0.11 (−0.30–0.07) −0.11 (−0.28–0.06)
4 0.07 (−0.07–0.21) 0.09 (−0.08–0.26) −0.11 (−0.30–0.07) −0.11 (−0.28–0.06)
HDP: Hypertensive Disorder of Pregnancy. GH: Gestational Hypertension. PWV: Pulse Wave Velocity (m/s). AIx75: Augmentation Index adjusted for Heart Rate (%).
RHI: Reactive Hyperemia Index. CIMT: Common Carotid Artery Intima-media thickness (um). 95%CI: 95% confidence interval for B. *:p < 0.05 and †:p < 0.01
when comparing HDP, Term Preeclampsia, Preterm Preeclampsia or GH to controls on linear regression analysis. Model 1: unadjusted. Model 2: adjusted for body
mass index (BMI), age. Model 3: adjusted for BMI, age and cardiovascular risk factors. Model 4: Model 3 adjusted for pregnancy characteristics.
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recommended to use for assessing cardiovascular risk, and to exclude
women with other conditions known to impact on this risk [2,3], e.g.
chronic hypertension or diabetes mellitus. Furthermore, no women
were breastfeeding, which otherwise could have impacted on blood
pressures [27].
Controls in our study did have an index pregnancy without hy-
pertension, hyperglycemia or delivery of a small for gestational age
baby, features linked to a higher cardiovascular disease risk [1]. Thus,
the controls constitute a very healthy group, increasing the power to
detect possible differences between women with a previous HDP and
controls.
Inter-observer bias was avoided for PWV, AIx75, and CIMT in our
study, since all examinations were performed by the same examiner,
and reproducibility was high. For RHI, EndoPAT-examinations are
generally reproducible [28].
Our study population has a potential for a self-selection bias. The
recruitment process for controls and cases was however identical, de-
creasing the risk of different bias. Furthermore, the mean PWV, AIx75,
and CIMT in our control group are within reference ranges, suggesting
that the controls are representative for the general population [24–26].
For RHI, we are not aware of any published reference ranges, and two
studies investigating RHI postpartum have found higher RHI in the
controls than in our study [7,8]. Interpretation and use of RHI in young
people is however difficult, as there is a paradoxical rise in RHI by age
in the younger part of the population [29].
The external validity of the study is strengthened by this being the
first study using updated definitions of preeclampsia and GH in group
analyses of PWV, AIx75, CIMT, or RHI [11]. However, using the old
preeclampsia definition (with mandatory proteinuria) only reclassified
9 women (Table 2), and did not significantly alter the level of any
vascular marker for the HDP subgroups.
Several studies have looked at one or more of PWV, AIx75, RHI, and
CIMT after an HDP. Few have however presented adjusted analyses.
Thus, published meta-analyses, finding elevated PWV, Augmentation
Index, and CIMT after HDP have not taken possible confounding factors
into account [5,6]. The by far largest study investigating any of these
markers postpartum, by Bergen et al [30], examined PWV 5–7 years
postpartum in nearly 5000 women, of which 300 had a previous HDP.
They found an increased PWV among women with previous GH, but not
preeclampsia, as compared to controls [30]. In contrast to our study,
the results in the preeclampsia group were not stratified by gestational
age. Low gestational age in preeclampsia is associated with increased
cardiovascular disease risk [1]. Our finding of an association between
preterm preeclampsia and adverse PWV levels is also supported by
Fig. 2. Regression analysis of vascular biomarkers levels in women with previous hypertensive disorder of pregnancy (95% confidence interval: grey dotted lines)
and controls (95% confidence intervals: black continuous lines). Means: filled circles. *p<0.05. 1: unadjusted. Model 2: adjusted for age and body mass index at 1
year postpartum. Model 3: Model 2 + adjustment for classical cardiovascular risk factors. Model 4: model 3 + adjustment for pregnancy characteristics, and
educational level.
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previous smaller studies [7,23]. Furthermore, although these three
mentioned studies all found significant differences in blood pressure
between groups, neither used blood pressure to adjust the PWV findings
[7,23,30].
In the study by Ehrenthal et al, a previous HDP significantly pre-
dicted AIx75 1 year postpartum after adjusting for some classical car-
diovascular risk factors, but not including blood pressure [31]. The
unadjusted AIx75 values were higher for controls and women with a
previous HDP than in our study, but detailed data about important
cardiovascular risk factors were not presented. Furthermore, 24% of the
total study population was of African-American origin, in contrast to
our study where nearly all were of white ethnicity.
We did not confirm CIMT differences between parous controls and
women with a previous HDP seen in some, but not all studies examining
CIMT in women with a previous HDP in the same postpartum time
frame [9,22,32–34]. Information on some important pregnancy char-
acteristics and/or cardiovascular risk factors was unavailable in all
these studies. This might have confounded the results [9,22,32,34].
Blaauw et al found increased CIMT 6 months postpartum in 22 women
with early-onset preeclampsia compared to 22 women with un-
complicated pregnancies. After adjusting for multiple classical cardio-
vascular risk factors, this association was not significant. The study was
however probably underpowered for multivariate regression analysis
[35]. The same group found no differences in CIMT when investigating
33 of the same women 5 years postpartum [36], in line with previous
studies investigating women with a previous HDP within a longer time
frame [37–39].
Our study shows that adverse levels of vascular markers in pre-
menopausal women with previous HDP are explained by levels of
classical cardiovascular risk factors. It is also debatable whether any of
the studied vascular markers independently predict cardiovascular
disease in general [2,3,10]. Furthermore, none have been validated in a
relatively young female population like ours. Our study indicates that
differences in vascular markers between women with a previous HDP
and controls found shortly after pregnancy (1 year) largely can be ex-
plained by differences in classical cardiovascular risk factors. These
classical risk factors are easier to measure, and thus more applicable in
the clinical setting. Our study does not however imply that follow-up
for primary prevention of cardiovascular disease is unnecessary in
women with a previous HDP. On the contrary, women with a previous
HDP in our study did indeed exhibit a worse cardiovascular risk profile
1 year postpartum, thus constituting a high-risk group for cardiovas-
cular disease development. This is supported by numerous epidemio-
logical studies [1]. Together with physical inactivity, poor diet, and
smoking, elevated BMI and blood pressure represent important mod-
ifiable cardiovascular risk factors. Thus, primary prevention of cardio-
vascular disease remains vital after an HDP. Such prevention should
probably commence as early as 1 year postpartum, focusing on mea-
surement and improvement of classical cardiovascular risk factors.
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